NFlection Therapeutics’ NFX-179 Gel Demonstrates Safety and Significant Reduction in p-ERK, a Key Biomarker Driving Neurofibroma Tumor Growth, in Positive Data From a 28-Day Phase 2a Clinical Trial Read More May 26, 2021
Apellis Announces U.S. Food and Drug Administration (FDA) Approval of EMPAVELI™ (pegcetacoplan) for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH) Read More May 14, 2021
Attralus Therapeutics Appoints Mark Timney as CEO and Expands Leadership Team with New Executives Read More May 10, 2021
Ventyx Biosciences Raises $114 Million Financing led by venBio Partners to Advance Diverse Pipeline of Immunology Programs Read More Mar 9, 2021
FogPharma® Announces $107 Million Series C Financing to Advance Direct β-Catenin Antagonist and Universal Druggability™ Platform Read More Mar 1, 2021
Artiva Biotherapeutics Raises $120 Million in Series B Financing to Advance Pipeline of Allogeneic NK Cell Therapies Read More Feb 26, 2021
